"10.1371_journal.pone.0065227","plos one","2013-06-03T00:00:00Z","Jung-Ok Lee; Cyril Auger; Dong Hyun Park; Moonkyu Kang; Min-Ho Oak; Kyoung Rak Kim; Valérie B Schini-Kerth","UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France; Research and Development Center, Hanwha Pharma. Co., Ltd., Chuncheon, Republic of Korea; Research Center, YangJi Chemicals, Suwon, Republic of Korea; College of Pharmacy, Mokpo National University, Muan, Jeonam, Republic of Korea","Conceived and designed the experiments: JOL CA MHO KRK VBSK. Performed the experiments: JOL DHP CA. Analyzed the data: JOL DHP. Wrote the paper: JOL CA DHP MK MHO VBSK.","Jung-Ok Lee, Moonkyu Kang and Kyoung Rak Kim are all employees of Hanwha Pharma. Co., Ltd, Chuncheon, Republic of Korea, whose company provided funding toward this study. Dong Hyun Park is an employee of YangJi Chemicals, Suwon, Republic of Korea, which is a daughter company of Hanwha. Hanwha has filed a European and US patent on YJP14 and endothelial dysfunction. The Korean FDA have approved further clinical studies regarding YJP-14 and endothelial dysfunction in diabetes. At present there are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","06","Jung-Ok Lee","JOL",7,TRUE,5,3,2,6,TRUE,TRUE,FALSE,0,NA,FALSE
